OD-001 ulcerative colitis study shows clinical response in 61% of higher-dose patients
Odyssey Therapeutics reports 27% remission with OD-001 in Phase 2a ulcerative colitis testing. Explore the findings and next clinical trials.
Pharma & Biotech